Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases.

Undesirable absorption, distribution, metabolism, excretion (ADME) properties are the cause of many drug development failures and this has led to the need to identify such problems earlier in the development process. This review highlights computational (in silico) approaches that have been used to identify the characteristics of ligands influencing molecular recognition and/or metabolism by the drug-metabolising enzyme UDP-gucuronosyltransferase (UGT). Current studies applying pharmacophore elucidation, 2D-quantitative structure metabolism relationships (2D-QSMR), 3D-quantitative structure metabolism relationships (3D-QSMR), and non-linear pattern recognition techniques such as artificial neural networks and support vector machines for modelling metabolism by UGT are reported. An assessment of the utility of in silico approaches for the qualitative and quantitative prediction of drug glucuronidation parameters highlights the benefit of using multiple pharmacophores and also non-linear techniques for classification. Some of the challenges facing the development of generalisable models for predicting metabolism by UGT, including the need for screening of more diverse structures, are also outlined.

[1]  Nicholas Bodor,et al.  Computer-aided drug design: the role of quantitative structure-property, structure-activity and structure-metabolism relationships (QSPR, QSAR, QSMR) , 2002 .

[2]  D. Benford,et al.  Observations on the accessibility of acceptor substrates to the active centre of UDP-glucuronosyltransferase in vitro. , 1976, Biochimica et biophysica acta.

[3]  Thomas Hofmann,et al.  Predicting CNS Permeability of Drug Molecules: Comparison of Neural Network and Support Vector Machine Algorithms , 2002, J. Comput. Biol..

[4]  C. Beddell,et al.  Quantitative structure-metabolism relationships for substituted benzoic acids in the rabbit: prediction of urinary excretion of glycine and glucuronide conjugates. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  C. Hansch,et al.  Structure--activity correlations in the metabolism of drugs. , 1968, Archives of biochemistry and biophysics.

[6]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[7]  G. Siest,et al.  A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids. , 1994, Molecular Pharmacology.

[8]  J. Miners,et al.  In silico insights: Chemical and structural characteristics associated with uridine diphosphate‐glucuronosyltransferase substrate selectivity , 2003, Clinical and experimental pharmacology & physiology.

[9]  J. Miners,et al.  Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. , 2004, Annual review of pharmacology and toxicology.

[10]  E Holmes,et al.  Quantitative structure-metabolism relationships (QSMR) using computational chemistry: pattern recognition analysis and statistical prediction of phase II conjugation reactions of substituted benzoic acids in the rat. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  M. Shimizu,et al.  Glucuronidation of propofol and its analogs by human and rat liver microsomes. , 2003, Biological & pharmaceutical bulletin.

[12]  T. Spector,et al.  Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. , 1991, Biochemical pharmacology.

[13]  E. Golovinsky,et al.  Inhibition of UDP-glucuronosyltransferase by 5'-O-amino Acid and Oligopeptide Derivatives of Uridine: Structure-Activity Relationships , 1998, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[14]  P. Mackenzie,et al.  Structural and functional studies of UDP-glucuronosyltransferases. , 1999, Drug metabolism reviews.

[15]  C. Hansch.  Comparative QSAR: Understanding Hydrophobic Interactions , 1995 .

[16]  Michael M. Mysinger,et al.  Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[17]  György M. Keserü,et al.  A virtual high throughput screen for high affinity cytochrome P450cam substrates. Implications for in silico prediction of drug metabolism , 2001, J. Comput. Aided Mol. Des..

[18]  J. Miners,et al.  Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. , 2003, Journal of medicinal chemistry.

[19]  M. Green,et al.  Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[20]  INHIBITION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE : A COMPARATIVE MOLECULAR FIELD ANALYSIS (COMFA) , 1996 .

[21]  S. Walker,et al.  Remarkable structural similarities between diverse glycosyltransferases. , 2002, Chemistry & biology.

[22]  Sean Ekins,et al.  Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.

[23]  C. Beddell,et al.  Prediction of urinary sulphate and glucuronide conjugate excretion for substituted phenols in the rat using quantitative structure-metabolism relationships. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  Erik Evensen,et al.  A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. , 2002, Journal of medicinal chemistry.

[25]  E. Golovinsky,et al.  Natural and synthetic inhibitors of UDP-glucuronosyltransferase. , 2001, Pharmacology & therapeutics.

[26]  R. T. Williams,et al.  Studies in detoxication. XLVII. The formation of ester glucuronides of aliphatic acids during the metabolism of 2-ethylbutanol and 2-ethylhexanol. , 1953, The Biochemical journal.

[27]  Arup K. Ghose,et al.  Pharmacophore Modelling: Methods,Experimental Verification and Applications , 2002 .

[28]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[29]  M. Delaforge,et al.  Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. , 2002, Molecular pharmacology.

[30]  C Mercier,et al.  Modeling alcohol metabolism with the DARC/CALPHI system. , 1991, Journal of medicinal chemistry.

[31]  G McKay,et al.  Quaternary ammonium-linked glucuronidation of 1-substituted imidazoles: studies of human UDP-glucuronosyltransferases involved and substrate specificities. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[32]  J. Miners,et al.  Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. , 2004, Molecular pharmacology.

[33]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[34]  D. Mccann,et al.  Quaternary ammonium-linked glucuronidation of 1-substituted imidazoles by liver microsomes: interspecies differences and structure-metabolism relationships. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[35]  R. T. Williams,et al.  Studies in detoxication. L. The isolation of methyl and ethyl glucuronides from the urine of rabbits receiving methanol and ethanol. , 1953, The Biochemical journal.

[36]  Dave Winkler.  The broader applications of neural and genetic modelling methods. , 2001, Drug discovery today.

[37]  J. Miners,et al.  Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism , 1994 .

[38]  Malcolm J. McGregor,et al.  Pharmacophore Fingerprinting. 1. Application to QSAR and Focused Library Design , 1999, J. Chem. Inf. Comput. Sci..

[39]  P. B. Wood,et al.  Kinetic studies of the metabolism of foreign organic compounds. III. The conjugation of phenols with glucuronic acid. , 1952, The Biochemical journal.

[40]  M. Redinbo,et al.  Structural insights into the promiscuity and function of the human pregnane X receptor. , 2002, Current opinion in drug discovery & development.

[41]  Paul A. Smith,et al.  Comparison of Linear and Nonlinear Classification Algorithms for the Prediction of Drug and Chemical Metabolism by Human UDP-Glucuronosyltransferase Isoforms , 2003, J. Chem. Inf. Comput. Sci..

[42]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[43]  J. Magdalou,et al.  Characterization of catechol glucuronidation in rat liver. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[44]  M. Green,et al.  Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[45]  K H Kim,et al.  Quantitative structure-activity relationships of the metabolism of drugs by uridine diphosphate glucuronosyltransferase. , 1991, Journal of pharmaceutical sciences.

[46]  C. Hansch,et al.  Lipophilic character and biological activity of drugs. II. The parabolic case. , 1973, Journal of pharmaceutical sciences.

[47]  G. Mulder,et al.  A rapid NAD+-linked assay for microsomal uridine diphosphate glucuronyltransferase of rat liver and some observations on substrate specificity of the enzyme. , 1975, The Biochemical journal.

[48]  J. Miners.  Evolution of drug metabolism: Hitchhiking the technology bandwagon , 2002, Clinical and experimental pharmacology & physiology.

[49]  J. Miners,et al.  Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. , 2002, Pharmacogenetics.

[50]  Han van de Waterbeemd,et al.  High-throughput and in silico techniques in drug metabolism and pharmacokinetics. , 2002 .

[51]  R. T. Williams,et al.  Studies in detoxication. XLVI. The metabolism of aliphatic alcohols; the glucuronic acid conjugation of acyclic aliphatic alcohols. , 1953, The Biochemical journal.

[52]  A. Good,et al.  3-D pharmacophores in drug discovery. , 2001, Current pharmaceutical design.

[53]  R. Glen,et al.  Quantitative structure-metabolism relationships for substituted benzoic acids in the rat. Computational chemistry, NMR spectroscopy and pattern recognition studies. , 1992, Biochemical pharmacology.

[54]  M Franchi,et al.  Human liver sulphotransferase and UDP-glucuronosyltransferase: structure-activity relationship for phenolic substrates. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[55]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[56]  Sean Ekins,et al.  Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[57]  M. Jackson,et al.  Examination of the substrate specificity of cloned rat kidney phenol UDP-glucuronyltransferase expressed in COS-7 cells. , 1988, Molecular Pharmacology.

[58]  Patrizia Crivori,et al.  The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples , 2000 .

[59]  J. Jones,et al.  Mechanistic studies of uridine diphosphate glucuronosyltransferase. , 1994, Chemico-biological interactions.